In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Galapagos NV

http://www.glpg.com

Latest From Galapagos NV

Roche Takes SCENIC Route On Genetic Modifiers

The Dutch biotech's C-suite tells Scrip that the technology it has developed and now licensed to Genentech allows it to systematically go through the whole genome gene by gene and discover what the modifier of a particular disease is.

Deals Companies

Ziritaxestat Phase II Success Gives Galapagos Something To Cheer

It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.

Clinical Trials Companies

Keeping Track: US FDA Has Clinical Questions For Tricida, Gilead And BioMarin; Enspryng And Winlevi Approved

The latest drug approval and decision news from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

Gilead’s RA Hopeful Filgotinib Hit By Complete Response Letter

Complete Response Letter is a major setback for Gilead and its partner Galapagos.

Commercial Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Other Names / Subsidiaries
    • Discovery Partners International
    • Inpharmatica Ltd.
    • Sareum Holdings plc.
    • ProSkelia
UsernamePublicRestriction

Register